[Ip-health] WHO publishes analysis of patent situation of new hepatitis treatments and expands prequalification to hepatitis

BEYER, Peter beyerp at who.int
Thu Sep 25 13:46:53 PDT 2014

WHO publishes analysis of patent situation of new hepatitis treatments

Resolution WHA67.6 requested the Director-General to assist Member States in ensuring equitable access to quality, effective, affordable and safe HCV treatments. For governments to identify ways of increasing access and affordability to these treatments, clarity about whether the medicines are patent protected in the respective countries is needed. To assist countries in this endeavor, the WHO Secretariat has published an analysis of the patent situation of seven new hepatitis treatments, including sofosbuvir:


Expressions of Interest for prequalification

To support national and global efforts to increase access to and the affordability of HIV/AIDS-related care and treatment, including treatment for hepatitis B and C, in both mono-infected and HIV co-infected patients, WHO, together with UNICEF, UNAIDS and UNITAID, invite applicants for selected pharmaceutical products to submit Expressions of Interest (EOI) for product evaluation. The EOI includes among other products
Sofosbuvir tablet, 400mg
Simeprevir capsule, 150mg
Ribavirin capsule, 200mg, 400mg, 600mg


Dr Peter Beyer
Senior Advisor
Public Health, Innovation and Intellectual Property
World Health Organization
CH - 1211 Geneva 27
Tel: +41 22 791 2507

More information about the Ip-health mailing list